MBX Biosciences, Inc. (MBX)
| Market Cap | 1.52B +287.3% |
| Revenue (ttm) | n/a |
| Net Income | -86.61M |
| EPS | -2.18 |
| Shares Out | 47.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 436,076 |
| Open | 31.91 |
| Previous Close | 31.79 |
| Day's Range | 31.21 - 32.89 |
| 52-Week Range | 9.43 - 45.85 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 61.40 (+92.78%) |
| Earnings Date | May 7, 2026 |
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy fo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for MBX stock is "Strong Buy." The 12-month stock price target is $61.4, which is an increase of 92.78% from the latest price.
News
MBX Biosciences price target raised to $56 from $50 at Stifel
Stifel raised the firm’s price target on MBX Biosciences (MBX) to $56 from $50 and keeps a Buy rating on the shares following the company’s investor day meeting. Published first…
MBX Biosciences price target raised to $70 from $66 at Barclays
Barclays raised the firm’s price target on MBX Biosciences (MBX) to $70 from $66 and keeps an Overweight rating on the shares. The MBX 4291 data in obesity is early…
MBX Biosciences price target raised to $86 from $76 at Citizens
Citizens raised the firm’s price target on MBX Biosciences (MBX) to $86 from $76 and keeps an Outperform rating on the shares. MBX Biosciences reported encouraging early data for MBX…
MBX Biosciences price target raised to $70 from $50 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on MBX Biosciences (MBX) to $70 from $50 and keeps a Buy rating on the shares. The firm is updating its…
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MBX Biosciences NASDAQ: MBX used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key devel...
MBX Biosciences Transcript: Status update
MBX 4291, a once-monthly GLP-1/GIP co-agonist, showed 7% mean weight loss and strong tolerability in phase I, with top-line 12-week MAD results expected in Q4. The pipeline includes a multi-mechanism amycretin and a triple agonist, supported by robust financials and a focus on patient-centric, flexible dosing.
MBX Biosciences Press release: Status update
MBX Biosciences issued a press release on May 11, 2026, disclosing material business information to investors.
MBX Biosciences Slides: Status update
MBX Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291
MBX Biosciences (MBX) announced multiple updates on its obesity portfolio, including preliminary blinded Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, which demonstrate a phar...
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)
MBX Biosciences Proxy statement: Proxy filing
MBX Biosciences filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
MBX Biosciences reports Q1 EPS (51c), consensus (58c)
“We continue to make excellent progress across our pipeline in 2026, including advancement toward initiation of our Phase 3 trial of once-weekly canvuparatide following a successful End-of-Phase 2 mee...
MBX Biosciences appoints Mark Soued as chief commercial officer.
MBX Biosciences (MBX) announced the appointment of Mark Soued as chief commercial officer. Most recently, Soued served as senior VP, head of U.S. at Alnylam Pharmaceuticals (ALNY). Published first on…
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Ma...
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
CARMEL, Ind. and BURLINGTON, Mass.
MBX Biosciences Quarterly report: Q1 2026
MBX Biosciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
MBX Biosciences Earnings release: Q1 2026
MBX Biosciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
CARMEL, Ind. and BURLINGTON, Mass.
MBX Biosciences Proxy statement: Proxy filing
MBX Biosciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
MBX Biosciences Proxy statement: Proxy filing
MBX Biosciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr...
MBX Biosciences initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of MBX Biosciences (MBX) with an Outperform rating and $75 price target
Options Volatility and Implied Earnings Moves Today, March 23, 2026
Today, several major companies are expected to report earnings: Bioline RX Ltd Sponsored ADR (BLRX), Lithium Argentina (LAR), MBX Biosciences, Inc. (MBX). Ahead of earnings, TipRanks shows you the exp...
MBX Biosciences files automatic mixed securities shelf
16:09 EDT MBX Biosciences (MBX) files automatic mixed securities shelf
MBX Biosciences reports Q4 EPS (49c), consensus (63c)
“2025 was a year of continued growth and execution for MBX, highlighted by the clinical validation of our Precision Endocrine Peptide platform,” said Kent Hawryluk, President and Chief Executive Offic...